HPV vaccines: purchase awarded u$s 33.3 M

The public-private consortium Sinergium Biotech turned out successful bidder in a tender that will deliver to the State 1.6 million doses of vaccines against him human papilloma virus, HPV. The product that arises from a strategic agreement with the North American MSD is rolled into an anchored process with $33.3 million.

–

Las vaccines regained value behind the COVID-19 crisis and in tune the Argentine state maintains the various bidding processes relating to the purchase of vaccines of a different nature.

Today, for example, the Ministry of Health of the Nation adjudicated a process which aims to acquire HPV vaccine batches. They bear the stamp of consortium private public Sinergium Biotech. See award

The tender that had opening date in the middle of June take the dollar as a reference currency and will involve the Ministry of Health of the Nation an outlay of $33.3 million ($4,687 million). It will be to stock up on 1.6 million quadrivalent vaccines against the human papilloma virus -HPV-, which is included in the National Vaccination Calendar and suitable for children from 11 years. See pre-award article / See article June

Synergium Biotech, whose main reference is the businessman Hugo Sigman will sell the brand to the State Silgard VPH. The product came under the umbrella of Sinergium in the year 2018when the ANMAT authorized the marketing of recombinant quadrivalent in the framework of a technology transfer agreement which closed with North American MSDwhich worldwide has as its emblem brand Gardasil. The version of Silgard HPV se it matters from the United Stateswhich then enters the conditioning stage final in the plant that Sinergium has in Garin. See tender / See ANMAT Sinergium device

according to what detailed in Administrative Decision 776which bears the signatures of the head of the Cabinet of Ministers, John Manzur; and the Minister of Health of the Nation, Carla Vizzottithe amount of $33.3 million will be charged to the Budget items of Financial year 2022.

The price quoted by Sinergium Biotech was consistent with the maximum value issued by the program on the basis that, for this tender, the State set maximum prices. The health portfolio had defined that the quoted amount could not exceed u$s 20,96 ($2,948.02) per dose, plus Value Added Tax in case it corresponds. and in the June opening actthe company offered a unit price of u$s 20.20 ($2,841.13), that is, a -3.63% compared to the maximum figure stated in the document.

The document also breaks down that the provision of doses -in prefilled syringe with needle or single dose vial with syringe and needle – will run for the account and charge of Sinergium Biotech and must be done in deposits to designate by Directorate for Control of Immunopreventable Diseaseswhich has as its owner Ana Carrerain the Metropolitan Area of Buenos Aires -AMBA-. In case of being finally awarded, Sinergium Biotech will have a within 20 days runs to make the delivery, from the Provision Request. It must be done in three stages: the first for the 40%; the Monday for him 30%; and the third for the other 30% remaining. See specifications